JP2022511394A5 - - Google Patents

Info

Publication number
JP2022511394A5
JP2022511394A5 JP2021517792A JP2021517792A JP2022511394A5 JP 2022511394 A5 JP2022511394 A5 JP 2022511394A5 JP 2021517792 A JP2021517792 A JP 2021517792A JP 2021517792 A JP2021517792 A JP 2021517792A JP 2022511394 A5 JP2022511394 A5 JP 2022511394A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
dose
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/109214 external-priority patent/WO2020063988A1/zh
Publication of JP2022511394A publication Critical patent/JP2022511394A/ja
Publication of JP2022511394A5 publication Critical patent/JP2022511394A5/ja
Pending legal-status Critical Current

Links

JP2021517792A 2018-09-30 2019-09-29 Cldn18の抗体及び化学療法薬の併用療法 Pending JP2022511394A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201811159863.8 2018-09-30
CN201811159863 2018-09-30
CN201811224605.3 2018-10-19
CN201811224605 2018-10-19
PCT/CN2019/109214 WO2020063988A1 (zh) 2018-09-30 2019-09-29 Cldn18的抗体和化疗药物的联合治疗

Publications (2)

Publication Number Publication Date
JP2022511394A JP2022511394A (ja) 2022-01-31
JP2022511394A5 true JP2022511394A5 (cg-RX-API-DMAC7.html) 2022-10-07

Family

ID=69950365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517792A Pending JP2022511394A (ja) 2018-09-30 2019-09-29 Cldn18の抗体及び化学療法薬の併用療法

Country Status (6)

Country Link
US (1) US20220033491A1 (cg-RX-API-DMAC7.html)
EP (1) EP3858384A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022511394A (cg-RX-API-DMAC7.html)
KR (1) KR20210072027A (cg-RX-API-DMAC7.html)
CN (1) CN112888458B (cg-RX-API-DMAC7.html)
WO (1) WO2020063988A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
CN114634566B (zh) * 2020-12-16 2023-09-19 广州百暨基因科技有限公司 一种抗Claudin18_2的抗原结合片段、抗体及其应用
KR20230124037A (ko) 2020-12-23 2023-08-24 소티오 바이오테크 에이.에스. 종양 특이적 claudin 18.2 항체-약물 접합체
WO2022206975A1 (zh) * 2021-04-02 2022-10-06 原启生物科技(上海)有限责任公司 Cldn18.2抗原结合蛋白及其用途
WO2023078386A1 (zh) * 2021-11-05 2023-05-11 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
EP4653017A1 (en) 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
WO2025026347A1 (en) * 2023-07-31 2025-02-06 Nanjing Legend Biotech Co., Ltd. Chimeric cytokine receptors and methods of use thereof
WO2025078686A1 (en) 2023-10-12 2025-04-17 Sotio Biotech A.S. Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer
CN122028934A (zh) * 2023-10-16 2026-05-12 江苏奥赛康生物医药有限公司 Cldn18_2抗体与化学治疗药物的组合及其应用
CN117430708B (zh) * 2023-12-21 2024-04-09 苏州近岸蛋白质科技股份有限公司 一种抗Claudin18.2抗体
CN118620072A (zh) * 2023-12-27 2024-09-10 上海博钒生物科技有限公司 一种肺炎克雷伯菌多糖单克隆抗体、其杂交瘤细胞株及其应用
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技(上海)有限公司 一种抗体偶联药物及其用途
WO2026064362A1 (en) * 2024-09-18 2026-03-26 The Children's Hospital Of Philadelphia Antibodies and chimeric antigen receptors binding to p2rx5 and methods of use for treating cancers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101602808B (zh) 2008-06-12 2012-06-20 上海市肿瘤研究所 特异性结合蛋白及其使用
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP2852409B1 (en) * 2012-05-23 2020-03-25 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
DK3254695T3 (da) 2012-05-23 2020-11-30 Astellas Pharma Inc Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
ES2699753T3 (es) * 2014-01-29 2019-02-12 Biontech Ag Mimótopos peptídicos de claudina 18.2 y sus usos
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用

Similar Documents

Publication Publication Date Title
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
JP2013520442A5 (cg-RX-API-DMAC7.html)
JP2023027199A5 (cg-RX-API-DMAC7.html)
JP2020508317A5 (cg-RX-API-DMAC7.html)
JP2016520082A5 (cg-RX-API-DMAC7.html)
JP2018508512A5 (cg-RX-API-DMAC7.html)
JP2012509889A5 (cg-RX-API-DMAC7.html)
JP2021528423A5 (cg-RX-API-DMAC7.html)
JP2019506403A5 (cg-RX-API-DMAC7.html)
JP2022515077A5 (cg-RX-API-DMAC7.html)
JP2017031160A5 (cg-RX-API-DMAC7.html)
JP2024533067A5 (cg-RX-API-DMAC7.html)
JP2013173775A5 (cg-RX-API-DMAC7.html)
IL292193B1 (en) Anti-b7-h1 antibodies for treating tumors
JP2017501167A5 (cg-RX-API-DMAC7.html)
JP2014522843A5 (cg-RX-API-DMAC7.html)
JP2020527332A5 (cg-RX-API-DMAC7.html)
JP2022512851A5 (cg-RX-API-DMAC7.html)
RU2015105786A (ru) Комбинированная терапия ингибиторами igf1r и pi3k
JP2024515879A5 (cg-RX-API-DMAC7.html)
JP2021511344A5 (cg-RX-API-DMAC7.html)
JP2020521798A5 (cg-RX-API-DMAC7.html)
US20210023211A1 (en) Combination of anti-fgfr4-antibody and bile acid sequestrant
JP2020535180A5 (cg-RX-API-DMAC7.html)
JP2024519449A5 (cg-RX-API-DMAC7.html)